LYTIX — Lytix Biopharma AS Share News
0.000.00%
Last trade - 00:00- NOK595.21m
- NOK505.59m
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program
Brief: Lytix Biopharma As Says Board Of Directors Has Therefore Decided Not To Proceed With Subsequent Offering Of New Shares
Brief: Lytix Biopharma Raises NOK 100 Mln in Private Placement
Brief: Lytix Biopharma Considers Private Placement, Retail Offer
Brief: Lytix Biopharma's Partner Verrica Announces Pricing Of Underwritten Public Offering
Brief: Lytix Biopharma Q3 Loss From Operations Widens To NOK 23 Mln
Brief: Lytix Biopharma Q2 Loss Narrows To NOK 21.4 Mln
Brief: Lytix Biopharma Q1 Loss Before Tax Narrows To NOK 18.2 Million
Brief: Lytix Biopharma Says Received Valid Applications To Subscribe For Offer Shares, Resulting In Total Size Of Offering Amounting To Nok 50 Million
Brief: Lytix Biopharma Says Raising Up To Nok 55 Mln
Brief: Lytix Biopharma Says Co Contemplated Launch Of Partially Guaranteed Offering Between 9.5 Mln -10.5 Mln New Shares, At Subscription Price Of NOK 5.24 Per Share
Brief: Lytix Biopharma Q4 Loss Narrows To NOK 18.6 Mln
Brief: Lytix Biopharma Q3 Loss For Period Widens To NOK 18.2 Million
05 Study Presented At Esmo 2023
Brief: Lytix Biopharma Granted Up To NOK 14.3 Mln Of Public Non-Dilutive Funding
Brief: Lytix Biopharma Q2 Loss For The Period Widens To NOK 31.4 Million